EventsAntibiotics 2026—Advances in Antimicrobial Action and Resistance
Published
This submission belongs to the session S2. Antimicrobials, Antimicrobial Resistance, and One Health of the event Antibiotics 2026—Advances in Antimicrobial Action and Resistance
Published date
04 May, 2026
Academic Editor
author-avatarJordi Vila
Citation
Márió Gajdács, Maisa Kasanga, Raphael Chanda, Doreen Shempela, Zachariah Mupila, Steward Mudenda, Mark Mwikisa, Edgar Simulundu, Duncan Chanda, Walter Muleya, Environmental Reservoirs of Carbapenem-Resistant Escherichia coli ST131 and ST69 in Zambia: A One Health Genomic Study, in Proceedings of Antibiotics 2026—Advances in Antimicrobial Action and Resistance, Barcelona, 11 May–14 May 2026, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Environmental Reservoirs of Carbapenem-Resistant Escherichia coli ST131 and ST69 in Zambia: A One Health Genomic Study

image
Raphael Chanda 4
Doreen Shempela 1
Zachariah Mupila 1
image
1. Zambia National Public Health Institute, Lusaka, Zambia, Zambia
2. Department of Public Health, Albert Szent-Györgyi Faculty of Medicine, University of Szeged, Hungary
3. MTA-SZTE Lendület “Momentum” Anthropogenic Stress and Plant Resilience Research Group; Közép fasor 52, 6726 Szeged, Hungary
4. ReAct Africa, Zambia
5. University of Zambia, Department of Pharmacy, Lusaka, Zambia, Zambia
6. Lusaka Trust Hospital, Lusaka, Zambia, Zambia
7. University Teaching Hospital Adult Center of Excellence, Lusaka, Zambia, Zambia
8. University of Zambia School of Veterinary Medicine, Lusaka, Zambia, Zambia
Abstract

Introduction: Carbapenem-resistant Escherichia coli (CREC) poses a critical public health threat globally. High-risk clones ST131 and ST69 drive the pandemic, yet their epidemiology in sub-Saharan Africa remains poorly characterized. We investigated the genomic features and epidemiological patterns of E. coli from human, animal, and environmental sources in Zambia using a comprehensive One Health approach.

Methods: Whole-genome sequencing was performed on 97 E. coli isolates (57 clinical, 40 environmental) collected from Lusaka, Zambia. Antimicrobial susceptibility testing, MLST typing, phylogroup assignment, and identification of AMR genes, plasmid replicons, and virulence factors were conducted. Statistical analyses included chi-square tests, Fisher's exact test, and principal component analysis to identify significant associations.

Results: Overall, 82.5% of isolates were multidrug-resistant. Carbapenem resistance was detected in 16.5% of isolates, significantly higher in environmental (25.0%) than clinical (10.5%) sources. The carbapenemase blaNDM-5 was exclusively found in environmental isolates (7.2%). ST131 dominated clinical isolates (41.2%), while ST69 was predominant environmentally (45.0%). Phylogroup B2 was most common clinically (50.9%), whereas phylogroup D was more prevalent environmentally (32.5%). Significant associations existed between specific STs and AMR genes (blaTEM-1, blaOXA-1 with ST131; p<0.01).

Conclusions: Environmental reservoirs in Zambia harbor a significant and concerning CREC burden, particularly ST69 and blaNDM-5-producing isolates. The distinct distribution of ST131 and ST69 between clinical and environmental settings suggests separate epidemiological pathways and transmission routes. These findings highlight the environment as a critical hub for CREC evolution and transmission, emphasizing the urgent need for integrated One Health surveillance and infection control strategies in the region.

Keywords
Escherichia coli
One health
genomics
carbapenemase
clinical
envionmental
Study of antimicrobial susceptibility of Enterococcus spp isolated from wild mammals from the Autonomous Community of Aragón (Spain)
Pharmacists’ observations and attitudes towards medication supply and community self-medication intentions during the COVID-19 pandemic: a qualitative, descriptive study